Md Yuzaiful Md Yusof Yuz6Yusof
1 week 5 days ago
#EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met all endpoints. ESSPRI improved too! Could be because strict concom DMARD inc. GC protocol @RheumNow https://t.co/FEhXfNPvfG
sheila RHEUMarampa
1 week 5 days ago
Multiparametric renal MRI in LN:
Structural MRI can differentiate bet. active and stable dse
Exudative = active inflamm
In quanti analysis, low ADC values may reflect fibrosis.
A potential non-invasive biomarker?
OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v
sheila RHEUMarampa
1 week 5 days ago
This retrospective cohort of NPSLE pts
showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI
Pts w/ diffuse symptoms - normal MRI except brain atrophy
Interesting to know how this can aid in future mgt strategies for NPSLE
OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 5 days ago
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 5 days ago
#EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #SLE or #SSc. These relapses were significant. Switching to BCMA-CAR or BCMA-TCE restored response. Should BCMA instead of CD19 be targeted initially?@RheumNow https://t.co/lgdsJQm3xY
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 5 days ago
#EULAR2026 POS0044 TO ASPIRIN OR NOT in asymptomatic antiphospholipid antibodies (aPL) carriers? A study in Spain reported 4.6% VTE & 4.1% ATE.
-Aspirin reduced thrombosis without increasing bleeding risk in asymptomatic aPL inc. those <3 lab points (isolated LA) @RheumNow https://t.co/NyVjAfjAKd
sheila RHEUMarampa
1 week 5 days ago
SLE & Dengue infxn?
This pop’n study from Brazil showed that #SLE pts who developed #dengue had sig. higher rates of mortality, DHF & hospital stay length vs. gen popn
These factors were found to have strong independent assoc w/SLE.
Abs010 @rheumnow #EULAR2026 https://t.co/DTDPiQRlAf
sheila RHEUMarampa
1 week 5 days ago
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use.
As a rheumatologist, do you vaccinate your patients?
#EULAR2026 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 5 days ago
#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16.
-Improvement as early as Week 4
-Low viral infections. Common AE: nasopharyngitis & headache.
-Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 5 days ago
#EULAR2026 Still undecided which session to attend? Please find my Conference Preview in the field of #SLE #lupus #biologics #targetedtherapy @RheumNow 😃
https://t.co/0m2p8mEgCQ https://t.co/C3xa5rPp9q
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression.
We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being
